Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:COYA NASDAQ:HLVX NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.79+2.5%$0.97$0.57▼$3.85$25.11M0.2790,598 shs25,690 shsCOYACoya Therapeutics$6.05-2.6%$6.24$4.65▼$10.24$103.86M0.2694,573 shs190,061 shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77762,303 shs1.24 million shsONCYOncolytics Biotech$1.28-2.3%$1.09$0.33▼$1.53$131.47M1.191.16 million shs925,847 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-3.63%-20.30%-33.70%-77.46%COYACoya Therapeutics0.00%-3.51%+6.51%+7.46%+1.51%HLVXHilleVax0.00%-0.48%+0.48%+12.97%+22.22%ONCYOncolytics Biotech0.00%+20.75%+36.13%+110.53%+35.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.79+2.5%$0.97$0.57▼$3.85$25.11M0.2790,598 shs25,690 shsCOYACoya Therapeutics$6.05-2.6%$6.24$4.65▼$10.24$103.86M0.2694,573 shs190,061 shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77762,303 shs1.24 million shsONCYOncolytics Biotech$1.28-2.3%$1.09$0.33▼$1.53$131.47M1.191.16 million shs925,847 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-3.63%-20.30%-33.70%-77.46%COYACoya Therapeutics0.00%-3.51%+6.51%+7.46%+1.51%HLVXHilleVax0.00%-0.48%+0.48%+12.97%+22.22%ONCYOncolytics Biotech0.00%+20.75%+36.13%+110.53%+35.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 3.00Buy$3.30318.25% UpsideCOYACoya Therapeutics 3.00Buy$16.50172.73% UpsideHLVXHilleVax 2.00Hold$2.00-4.31% DownsideONCYOncolytics Biotech 2.80Moderate Buy$5.00290.63% UpsideCurrent Analyst Ratings BreakdownLatest AKTX, ONCY, HLVX, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/4/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/25/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/25/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.008/8/2025HLVXHilleVaxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.007/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.007/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACOYACoya Therapeutics$3.55M28.51N/AN/A$2.37 per share2.55HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%9/25/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.24N/AN/AN/AN/A-61.05%-53.61%11/5/2025 (Estimated)HLVXHilleVax-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)Latest AKTX, ONCY, HLVX, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025AKTXAkari Therapeutics-$0.09N/AN/AN/AN/AN/A8/12/2025Q2 2025COYACoya Therapeutics-$0.22-$0.36-$0.14-$0.36$0.78 million$0.16 million8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/A8/6/2025Q2 2025HLVXHilleVax-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19COYACoya TherapeuticsN/A7.437.43HLVXHilleVaxN/A26.3926.39ONCYOncolytics BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%COYACoya Therapeutics39.75%HLVXHilleVax86.42%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%COYACoya Therapeutics12.00%HLVXHilleVax24.90%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableAKTX, ONCY, HLVX, and COYA HeadlinesRecent News About These CompaniesLake Street Keeps Their Buy Rating on Oncolytics Biotech (ONCY)September 10, 2025 | theglobeandmail.comOncolytics Biotech (ONCY) Receives a Hold from JonesTradingSeptember 10, 2025 | theglobeandmail.comBreakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape MarketSeptember 9, 2025 | newswire.caOncolytics Biotech Reports Promising Results in Metastatic Colorectal Cancer StudiesSeptember 8, 2025 | tipranks.comOncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway DiscussionsSeptember 8, 2025 | prnewswire.comOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal TumorsSeptember 2, 2025 | prnewswire.comCancer Treatment Revolution Drives $903B Market as New Therapies Gain MomentumAugust 28, 2025 | baystreet.caOncolytics Biotech® Announces Upcoming Investor Conferences in SeptemberAugust 28, 2025 | prnewswire.comHere's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn SituationAugust 27, 2025 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Raised to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comLake Street Capital Begins Coverage on Oncolytics Biotech (NASDAQ:ONCY)August 15, 2025 | marketbeat.comLake Street Initiates Coverage of Oncolytics Biotech (ONCY) with Buy RecommendationAugust 14, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of ShareholdersAugust 12, 2025 | finanznachrichten.deOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersAugust 11, 2025 | prnewswire.comJonesTrading Remains a Hold on Oncolytics Biotech (ONCY)August 10, 2025 | theglobeandmail.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for PelareorepAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock ExchangeAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Files SEC Report Incorporating Information CircularAugust 8, 2025 | tipranks.comOncolytics Biotech Reports Reduced Losses in Q2 2025 Financial UpdateAugust 8, 2025 | tipranks.comOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for PelareorepAugust 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTX, ONCY, HLVX, and COYA Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.79 +0.02 (+2.47%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.79 +0.01 (+0.63%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Coya Therapeutics NASDAQ:COYA$6.05 -0.16 (-2.58%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.18 +0.14 (+2.23%) As of 09/12/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.HilleVax NASDAQ:HLVX$2.09 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.09 0.00 (0.00%) As of 09/12/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$1.28 -0.03 (-2.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.17%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
